THE PLACE FOR A NEW NATIONAL2MADE ΑΒ2BLOCKER, PROXODOLOL, IN THE TREATMENT OF HYPERTENSIVE CRISES

Abstract

A limited variety of hypotensive drugs is recommended for the treatment of I class hypertensive crises, requiring rapid action, high efficacy and having appropriate formulations available (sublingual or parenteral forms. Among β- blockers III generation drugs with additional vasodilative properties have such pharmacodynamic properties. A nationalmade αβ-blocker Proxodolol is among them. Proxodolol’s efficacy was studied in 20 in-patients with I class hypertensive crises. The drug had rapid hypotensive effect when introduced intravenously as 1-3 ml (20-30 mg), with the onset of action in 5 minutes and peak in 42,1 minutes. Maximal SBP decrease was 25,1%, DBP – 20,9%. The duration of hypotensive effect reached 3,9 hours in average. Complete hypotensive effect was noted in 17 patients. Proxodolol’s tolerability was good, with vertigo and drowsiness as the most common adverse effects.